Dr. David Samadi Helps People Find a New Way to Look After Their Health

It’s no secret that it takes a long time to become a doctor. People seldom consider just how much knowledge is earned during that period. And once a medical doctor begins practicing he’ll continue to learn and innovate. This means that doctors have a wealth of knowledge that the average person lacks.

While people seldom notice that difference in knowledge, doctors know how much of a problem it can be. That’s why some of the leading figures in the medical industry are working hard to promote better understanding of health and medicine. The bigger the name the more significant the news. That’s why the news that Dr. David Samadi has found a new way to educate the public is so exciting.

Dr. David Samadi is hosting a new show called Sunday Housecall. The show is intended to help people get a better idea of what’s involved with modern medicine. The basic foundation of the show involves Dr. David Samadi teaching the audience about various medical topics. But the key defining point of the show is that it’s primarily an interactive process. The audience is always able to reach out and ask questions. Likewise other viewers will be able to benefit from those answers as well. If one person has a question it’s fairly safe to assume that others will too. This discussion format acts as a perfect way to educate the public on some very complex subjects.

Dr. David Samadi also brings in experts within various fields to get their take on the latest news from the medical world. This two tiered method of discussing medicine offers quite a few advantages for viewers. Dr. Samadi is able to act as quality control for the flow of information. He’s a fantastic public speaker who also possesses expertise in the field. As such, he can make sure that any guests live up to those standards as well. In doing so the audience has the advantage of always hearing from the experts in any given field of medicine.

Of course all of that hinges on the expertise of Dr. David Samadi himself. The doctor was offered the position for good reason. He’s a practicing physician, operating out of Lenox Hill Hospital. In that position he’s responsible for a wide range of duties. This extends all the way up to overseeing the robotics surgery program. The continuing integration of robots within medical care is about as cutting edge as medicine gets, and learn more about Dr. Samadi.

Part of what made Dr. Samadi so successful within the field is an understanding of how various schools of medicine can work together. For example, he quickly integrated his work with robotics into standard patient care. Doing so streamlines the surgical process while also providing real world feedback for the devices. This ability to push technologies and techniques into different fields is part of what makes him such a good host. He understands exactly how to take information from the medical world and translate it into something the public can understand, and http://reporterexpert.com/weekly-medical-insight-dr-david-samadi/.

Oncotarget and their aim at life without disease

Oncotarget is a weekly medical journal that is published twice weekly. Specializing in oncology the journal has been open-access to enable more people to make use of it. A publication of Impact Journals, Oncotarget was launched in 2010 and has Mikhail Blagosklonny and Andrei V. Gudkov of Roswell Park Cancer Institute as the chief editors. Operating under Creative Commons 3.0 License, the journal has been rated to have had an impact factor of 5.16 in the year 2016.The journal’s administrators announced on the journal’s official website that due to increased demand and circulation that the journal would get published twice weekly – Tuesdays and Fridays.

The auditors attribute the rising impact factor of the journal to insightful, constructive multiple peer-review articles that have enabled the contributing researchers to improve the impact size of their research. Oncotarget is ranked top among oncology journals by Scimago Journal and Country Rank (SJR) The ranking, which compared 50 publications, showed Oncotarget leading with over 6300 documents published in 2016 followed by followed by Oncology Letters with 2545 documents. Molecular Medicine Reports ranks third with 1475 papers while Asian Pacific Journal of Cancer Prevention comes fourth with 1068 papers. The ranking also considers other aspects such as the total number of times the articles in the journal have been cited by other authors and even the average number every document has been mentioned.

Oncotarget publishers say that their mission is ‘to make scientific results rapidly and widely available’ and to attain maximum impact levels of research by the use of insightful peer-reviews. The website also describes the journal as free-access, multidisciplinary and traditional in approach. The publication is released online, but the editors say that hard copies can get produced on demand. By this, they hope to facilitate quick sharing of remarkable discoveries. The journal further expects to create a link between biomedical fields and eliminate the divide between various boundaries. Also, the publication hopes to champion the application of fundamental and advanced scientific interventions to alleviate disease and promote health.Being under the leadership of senior scientists the publication aims at attaining life devoid of disease.

The Medical Journey and Contributions of Prof. Mikhail Blagosklonny

Prof. Mikhail Blagosklonny has a few decades of experience under his belt. He has received his education from some of the leading Russian institutions and has done research in some of the biggest research centers in the United States of America. Prof. Mikhail Blagosklonny has also contributed through his works as an editor and a writer.

Born in Russia, Prof. Mikhail Blagosklonny spent his early life in his home country. He received his higher education from some of the renowned institutions of Russia such as the First Pavlov State Medical University. Prof. Mikhail Blagosklonny graduated from First Pavlov with a major in Experimental Medicine as well as Cardiology. After earning his Ph. D., Prof. Mikhail Blagosklonny also pursued an M. D. in Internal Medicine from the First Pavlov State Medical University.

Read more: http://www.aging-us.com/article/100591/text

Upon finishing his studies, Prof. Mikhail Blagosklonny moved to the United States of America in order to join a team of experts and embark n his career in the medical field. He moved to New York City where he started teaching oncology at the New York Medical College in 2002 as well as doing some medical research on the side. He was at the post of associate professor of medicine for a handful of years. After that, Prof. Mikhail Blagosklonny became a member of another institution where he could conduct further medical research – the Ordway Research Institute. That institution was a good fit for Prof. Mikhail Blagosklonny for a handful of years, but he wanted to continue his research in more detail in the field of cancer as oncology was one of the two primary fields in which

Prof. Mikhail Blagosklonny had specialized. Prof. Mikhail Blagosklonny could not narrow down his research at the Ordway Research Center, and so he moved on to become a part of the Roswell Park Cancer Institute in the year of 2009. Prof. Mikhail Blagosklonny is still working there.

As a part of the Roswell Park Cancer Institute, Prof. Mikhail Blagosklonny has been able to focus on his research and conduct his studies more in detail. He has also been able to work in the field of biogerontology as Prof. Mikhail Blagosklonny is deeply dedicated to his studies of aging and is determined to find solutions that would slow down the process.

Medical research has not been the only thing that Prof. Mikhail Blagosklonny is dedicated to. He has written and published over one hundred medical papers over the course of his career. Not only that, but Prof. Mikhail Blagosklonny is also one of the two editors in chief of a rising medical journal which is called Oncotarget. The other chief editor is a colleague of Prof. Mikhail Blagosklonny. While the medical journal of Oncotarget is the first journal that Prof. Mikhail Blagosklonny is improving, there are two more medical journals that he edits. There is also the journal called Cell Cycle which published the latest research on aging and biogerontology as a whole. The other journal is called Aging as that is its subject as well.

Prof. Mikhail Blagosklonny has a few decades of experience under his belt. He has received hs education from some of the leading Russian institutions and has done research in some of the biggest research centers in the United States of America. Prof. Mikhail Blagosklonny has also contributed through his works as an editor and a writer. Visit classroomvoices.org to read more about Mikhail.

Born in Russia, Prof. Mikhail Blagosklonny spent his early life in his home country. He received his higher education from some of the renowned institutions of Russia such as the First Pavlov State Medical University. Prof. Mikhail Blagosklonny graduated from First Pavlov wth a major in Experimental Medicine as well as Cardiology. After earning his Ph. D., Prof. Mikhail Blagosklonny also pursued an M. D. in Internal Medicine from the First Pavlov State Medical University.

Upon finishing his studies, Prof. Mikhail Blagosklonny moved to the United States of America in order to join a team of experts and embark n his career in the medical field. He moved to New York City where he started teaching oncology at the New York Medical College in 2002 as well as doing some medical research on the side. He was at the post of associate professor of medicine for a handful of years. After that, Prof. Mikhail Blagosklonny became a member of another institution where he could conduct further medical research – the Ordway Research Institute. That institution was a good fit for Prof. Mikhail Blagosklonny for a handful of years, but he wanted to continue his research in more detail in the field of cancer as oncology was one of the two primary fields in which

Prof. Mikhail Blagosklonny had spesialized. Prof. Mikhail Blagosklonny could not narrow down his research at theOrdway Research Center, and so he moved on to become a part of the Roswell Park Cancer Institute in the year of 2009. Prof. Mikhail Blagosklonny is still working there.

As a part of the Roswell Park Cancer Institute, Prof. Mikhail Blagosklonny has been able to focus on his research and conduct his studies more in detail. He has also been able to work in the field of biogerontology as Prof. Mikhail Blagosklonny is deeply dedicated to his studies of aging and is determined to find solutions that would slow down the process.

Medical research has not been the only thing that Prof. Mikhail Blagosklonny is dedicated to. He has written and published over one hundred medical papers over the course of his career. Not only that, but Prof. Mikhail Blagosklonny is also one of the two editors in chief of a rising medical journal which is called Oncotarget. The other chief editor is a colleague of Prof. Mikhail Blagosklonny. While the medical journal of Oncotarget is the first journal that Prof. Mikhail Blagosklonny is improving, there are two more medical journals that he edits. There is also the journal called Cell Cycle which published the latest research on aging and biogerontology as a whole. The other journal is called Aging as that is its subject as well.

Dr. Mikhail Blagosklonny: Revolutionary Aging Doctor

Dr. Mikhail Blagoskloony is a scientist who studies aging and cancer. He earned his M.D in internal medicine and his PhD in external medicine from the First Pavlov State Medical University of St. Petersburg. In 2002, he was appointed associate professor of medicine at New Your Medical College. Shortly thereafter he accepted a position as senior scientist at Ordway Research Institute. Since 2009 Dr. Mikhail Blagoskloony is working as a professor of Oncology at Roswell Park Cancer Institute in New York. View his LinkedIn profile

Dr. Blagoskloony formulated a hypothesis about the possible role of TOR (Target of rapamycin) signaling in aging and cancer by the use of rapamcyin, a cancer drug as a possible treatment for life extension. In on words, it would be an anti-aging drug that would slow or reverse aging. While Dr. Blagoskloony was working on cancer patients, he realized that the same qualities that made rapamycin effective at slowing tumor growth, would possibly slow aging as well. In fact the doctor even takes rapamcyin himself.

His role as professor of Oncology at Roswell Park Cancer Institute in New York is to help facilitate the development of new anti-cancer strategies and development and methods of cancer protection that are not limited to: therapy, selective combination anticancer drugs, and prevention of cancer by slowing down organismal aging. of In addition to Mikhail Blagoskloony’s groundbreaking work in his field he is Founding Editor and Editor-in-Chief for Cell Cycle and Associate Editor of the following publications: PLOS ONE, Cancer Biology & Therapy, American Journal of Pathology, Cell Death & Differentiation, Autophagy, Cancer Research, and International Journal of Cancer. Follow Mikhail on Loop

 

Seattle Genetics’ Strategic Plans for New Cancer Drugs and Expanding its Workforce

Seattle Genetics recently released a cancer drug, Adcetris, its first approved drug. The company, as an established cancer research center, is trying to increase the usage of the drug. According to a statement released by Seattle Genetics’ CEO Clay Siegall, Adcetris is currently being tested in over 70 clinical trials. The experiments mainly focus on the different types of lymphomas disease. The company also announced that a third phase clinical trial is being conducted for Hodgkin lymphoma. Dr. Siegall pointed out that the trial will impact primarily on the cancer-oriented medical initiatives undertaken by his company.

The Current and Projected Commercial Performance of Adcetris

Adcetris has amassed over $226 in the US and Canadian markets in the last one year. Seattle Genetics projects the sales to range between $255 and $275 million in 2016. In partnership with Takeda Pharmaceuticals, the company currently sells the cancer drug to patients and medical facilities outside North America.

Other Drugs Developed by Seattle Genetics

Seattle Genetics has 12 drugs in its cancer drugs roster excluding Adcetris. A new drug, known as 33A, is still in the 3rd phase of its clinical trial. The drug was developed to treat acute cases of myeloid leukemia. The company has also developed two bladder cancer drugs and one for breast cancer. Dr. Siegall said that relevant details regarding these three drugs would be released before the end of 2016.

Job Opportunities

Besides developing several cancer drugs, Seattle Genetics is also planning to hire 100 employees who will work in its U.S. headquarters. The company is also planning to hire 20 employees who will be based in its Switzerland branch. Seattle currently comprises of over 800 employees.

Clay Siegall

Dr. Siegall is the current president and chief executive officer of Seattle Genetics. He co-founded the company in 1998, and he serves as the chair of its board of directors to date. He served at Ultragenyx in 2014 as a board member.

Dr. Siegall has worked for the Bristol-Myers Squibb Pharmaceutical Research Institute, the National Institute of Health as well as the National Cancer Institute. He graduated from the University of Maryland with a B.S in Zoology and George Washington University with a Ph.D. in Genetics.

Seattle Genetics Advancing Cancer Treatments through Engineered Monoclonal Antibodies

Chemotherapy drugs interfere with the rapidly growing cells of the body. It affects cells like those of the stomach lining, skin, hair and fingernails. This is why chemotherapy causes temporary side effects (late effects) to patients. The late effects differ from patient to patient depending on the type of medicines used. New therapeutic treatments have been designed to treat cancer by targeting malignant cells, reducing damage to normal tissues and reducing the toxic effects of traditional chemotherapy.

Seattle Genetics is a biotechnology company that aims at revolutionizing the treatment of cancer by developing engineered monoclonal antibodies. The company is a leading developer of antibody-drug conjugates (ADCs). The technology has resulted in therapies that are better tolerated and can be used with chemotherapy to improve patient outcomes without a considerable increase in toxicities.

Clay Siegall has produced the first product in the new class of ADCs. The product is known as ADCETRIS® (brentuximab vedotin) and was approved by the FDA in 2011. Seattle Genetics is further expanding the ADCETRIS opportunity by carrying out an extensive clinical development program to evaluate the drug’s potential in treating CD30-expressing lymphomas. Besides ADCETRIS, the company has a broad pipeline to address various types of cancers like colon cancer, leukemia, solid tumors, and breast cancer among others.

Seattle Genetics was founded in 1977 by Dr. Clay Siegall and Dr. H. Perry Fell. Dr. Siegall is a scientist by profession and has almost 20 years of experience in therapeutic drug treatment and cancer research. Before co-founding the biotechnology company, Dr. Siegall worked with the Bristol-Myers Squibb Pharmaceutical Research Institute as a senior research investigator from 1991 and 1995 and a chief scientist from 1995 to 1997. He served as a staff fellow and biotechnology fellow at the National Cancer Institute, and National Institutes of Health from 1988 to 1991.

Clay Siegall has enabled Seattle Genetics to achieve most of its goals. The achievements include initiating clinical trials of SGN-15 and entering into partnership agreements with numerous biotechnology and pharmaceutical companies. The partnerships have been vital in expanding the company’s technology and maintaining its financial health.

Learn more:

http://executives.findthecompany.com/l/23957/Dr-Clay-B-Siegall-PhD

https://twitter.com/seattlegenetics/status/730438999307755521